NASDAQ:IMGN ImmunoGen (IMGN) Stock Price, News & Analysis Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$31.23▼$31.2350-Day Range$31.23▼$31.2352-Week Range$3.61▼$31.25Volume40 shsAverage Volume8.78 million shsMarket Capitalization$8.32 billionP/E RatioN/ADividend YieldN/APrice Target$26.48 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSustainabilityTrends Get ImmunoGen alerts: Email Address ImmunoGen MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside15.2% Downside$26.48 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.77Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings Growth362.50%From $0.08 to $0.37 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.07 out of 5 starsMedical Sector821st out of 936 stocksBiotechnology Industry5th out of 11 stocks 1.1 Analyst's Opinion Consensus RatingImmunoGen has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 3 buy ratings, 9 hold ratings, and no sell ratings.Amount of Analyst CoverageImmunoGen has received no research coverage in the past 90 days.Read more about ImmunoGen's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for IMGN. Previous Next 0.0 Dividend Strength Dividend YieldImmunoGen does not currently pay a dividend.Dividend GrowthImmunoGen does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreImmunoGen has received a 69.84% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for ImmunoGen is -0.77. Previous Next N/A News and Social Media Coverage Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, ImmunoGen insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.07% of the stock of ImmunoGen is held by insiders.Percentage Held by Institutions90.50% of the stock of ImmunoGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about ImmunoGen's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for ImmunoGen are expected to grow by 362.50% in the coming year, from $0.08 to $0.37 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of ImmunoGen is -100.74, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioImmunoGen has a P/B Ratio of 43.99. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About ImmunoGen Stock (NASDAQ:IMGN)ImmunoGen, Inc., a commercial-stage biotechnology company, focuses on developing and commercializing the antibody-drug conjugates (ADCs) for cancer patients. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), for the treatment of platinum-resistant ovarian cancer; and a cell-surface protein expressed in various epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers, as well as Pivekimab sunirine, a CD123-targeting ADC that is in Phase II clinical trial for treating acute myeloid leukemia and blastic plasmacytoid dendritic cell neoplasm. Its preclinical programs include IMGC936, an ADC in co-development with MacroGenics, Inc.; and IMGN151, an anti-FRa product candidate. The company has collaborations with Roche; Amgen/Oxford BioTherapeutics; Bayer HealthCare AG; Eli Lilly and Company; Novartis Institutes for BioMedical Research, Inc.; CytomX Therapeutics, Inc.; Fusion Pharmaceuticals Inc.; Debiopharm International SA; and MacroGenics, Inc. ImmunoGen, Inc. was founded in 1980 and is headquartered in Waltham, Massachusetts. As of February 12, 2024, ImmunoGen, Inc. operates as a subsidiary of AbbVie Inc.Read More Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. IMGN Stock News HeadlinesApril 25, 2024 | seekingalpha.comPolaris Global Equity Composite Q1 2024 CommentaryApril 25, 2024 | investing.comLazard posts first-quarter profit on deals, assets boostJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.April 23, 2024 | seekingalpha.com3 Potential Biopharma Buyout TargetsMarch 22, 2024 | marketwatch.comAbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen DealFebruary 21, 2024 | msn.comAbbVie plans to offer senior notes to fund Immunogen, Cerevel dealsFebruary 19, 2024 | ca.finance.yahoo.comCERE Aug 2024 30.000 callFebruary 12, 2024 | markets.businessinsider.comBarclays Keeps Their Hold Rating on ImmunoGen (IMGN)July 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.February 12, 2024 | msn.comAbbVie revises Q1 earnings outlook as ImmunoGen deal closesFebruary 9, 2024 | finance.yahoo.comIs ImmunoGen (IMGN) Outperforming Other Medical Stocks This Year?February 9, 2024 | seekingalpha.comFinal Countdown: AbbVie's Imminent Closure With ImmunoGen And What It MeansFebruary 9, 2024 | msn.comImmunoGen Set to Merge with AbbVie, Awaiting Final ApprovalFebruary 9, 2024 | finance.yahoo.comImmunoGen (IMGN) Soars 5.7%: Is Further Upside Left in the Stock?February 2, 2024 | finance.yahoo.comImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 2, 2024 | finance.yahoo.comImmunoGen, Inc. (IMGN) Interactive Stock Chart - Yahoo FinanceJanuary 9, 2024 | finance.yahoo.comHow ImmunoGen (IMGN) Stock Stands Out in a Strong IndustryJanuary 4, 2024 | nasdaq.comIMGN Quantitative Stock AnalysisSee More Headlines Receive IMGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for ImmunoGen and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2023Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:IMGN CUSIP45253H10 CIK855654 Webwww.immunogen.com Phone(781) 895-0600Fax781-895-0611Employees277Year Founded1981Price Target and Rating Average Stock Price Target$26.48 High Stock Price Target$31.26 Low Stock Price Target$16.00 Potential Upside/Downside-15.2%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.31) Trailing P/E RatioN/A Forward P/E Ratio390.38 P/E GrowthN/ANet Income$-222,930,000.00 Net Margins-25.56% Pretax Margin-25.24% Return on Equity-22.11% Return on Assets-13.53% Debt Debt-to-Equity Ratio0.13 Current Ratio5.70 Quick Ratio5.65 Sales & Book Value Annual Sales$287.61 million Price / Sales28.91 Cash FlowN/A Price / Cash FlowN/A Book Value$0.71 per share Price / Book43.99Miscellaneous Outstanding Shares266,264,000Free Float252,764,000Market Cap$8.32 billion OptionableOptionable Beta1.18 Social Links 7 Stocks to Buy And Hold ForeverClick the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free Report Key ExecutivesMr. Mark Joseph Enyedy (Age 60)President, CEO & Director Comp: $1.28MDr. Michael J. Vasconcelles M.D. (Age 61)Ph.D., Chief Medical Officer Comp: $304.62kMs. Lauren A. White M.B.A. (Age 45)Senior VP & Chief Financial Officer Anabel ChanHead of Investor RelationsMr. Daniel S. Char J.D. (Age 62)Senior VP, Chief Legal Officer & Secretary Ms. Courtney O'KonekSenior Director of Corporate Communications & Investor RelationsMs. Audrey BerganSenior VP & Chief HR OfficerDr. Theresa G. Wingrove (Age 66)Senior Vice President of Regulatory Affairs & Quality Comp: $548.21kMs. Isabel KalofonosSenior VP & Chief Commercial OfficerMore ExecutivesKey CompetitorsRhythm PharmaceuticalsNASDAQ:RYTMKiniksa PharmaceuticalsNASDAQ:KNSASupernus PharmaceuticalsNASDAQ:SUPNOcular TherapeutixNASDAQ:OCULArcutis BiotherapeuticsNASDAQ:ARQTView All CompetitorsInsiders & InstitutionsWalleye Trading LLCSold 40,200 shares on 5/17/2024Ownership: 0.000%PEAK6 Investments LLCSold 7,500 shares on 5/15/2024Ownership: 0.000%Picton Mahoney Asset ManagementSold 247,700 shares on 5/9/2024Ownership: 0.000%Fifth Lane Capital LPSold 33,600 shares on 5/2/2024Ownership: 0.000%Theresa WingroveSold 187,667 sharesTotal: $5.56 M ($29.64/share)View All Insider TransactionsView All Institutional Transactions IMGN Stock Analysis - Frequently Asked Questions How were ImmunoGen's earnings last quarter? ImmunoGen, Inc. (NASDAQ:IMGN) issued its earnings results on Monday, July, 31st. The biotechnology company reported ($0.02) EPS for the quarter, beating the consensus estimate of ($0.16) by $0.14. The business's quarterly revenue was up 485.9% on a year-over-year basis. What is Mark J. Enyedy's approval rating as ImmunoGen's CEO? 16 employees have rated ImmunoGen Chief Executive Officer Mark J. Enyedy on Glassdoor.com. Mark J. Enyedy has an approval rating of 64% among the company's employees. Does ImmunoGen have any subsidiaries? The following companies are subsidiaries of ImmunoGen: Hurricane LLC, ImmunoGen BioPharma (Ireland) Limited, ImmunoGen Europe Limited, and ImmunoGen Securities Corp.. What other stocks do shareholders of ImmunoGen own? Based on aggregate information from My MarketBeat watchlists, some other companies that ImmunoGen investors own include Pfizer (PFE), NVIDIA (NVDA), Micron Technology (MU), Immunomedics (IMMU), Advanced Micro Devices (AMD), AbbVie (ABBV) and Gilead Sciences (GILD). This page (NASDAQ:IMGN) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ImmunoGen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ImmunoGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.